150-600 mg/day in 2 or 3 divided doses. Neuropathic pain Initially 150 mg/day. May be increased to 300 mg/day after an interval of 3-7 days. Max: 600 mg/day after an additional 7-day interval, if needed. Fibromyalgia Initially 150 mg/day. May be increased to 300-450 mg/day in 2 divided doses. Max: 600 mg/day after an additional wk, if needed. Epilepsy Initially 150 mg/day. May be increased to 300 mg/day after 1 wk. Max: 600 mg/day after an additional wk. GAD Initially 150-600 mg/day given as 2 or 3 divided doses. May be increased to 300 mg/day after 1 wk. Max: 600 mg/day after an additional wk.
Lapp lactase deficiency or glucose-galactose malabsorption. Adjust hypoglycemic medications in diabetic patients who gain wt during treatment. Discontinue immediately if symptoms of angioedema occur. Discontinue treatment if transient visual blurring & other changes in visual acuity occur. W/drawal symptoms have been observed after discontinuation. Evaluate patients for history of drug abuse & observe for signs of misuse, abuse, dependence (eg, development of tolerance, dose escalation, drug-seeking behavior). Renal impairment. CHF. May affect ability to drive or operate machinery. Pregnancy & lactation. Elderly >65 yr. Childn <12 yr.
May potentiate the effects of ethanol or lorazepam. Additive in the impairment of cognitive & gross motor function caused by oxycodone. Resp failure & coma w/ other CNS depressant medications. Reduced lower GIT function (eg, intestinal obstruction, paralytic ileus, constipation) w/ medications that have the potential to produce constipation eg, opioid analgesics.
Sign Out
